NO20043569L - Metabolitter av(3-{[4-tert-butyl-benzyl)-(pyridin-3-sulfonyl)-amino]-metyl}-fenoksy)-eddiksyre - Google Patents

Metabolitter av(3-{[4-tert-butyl-benzyl)-(pyridin-3-sulfonyl)-amino]-metyl}-fenoksy)-eddiksyre

Info

Publication number
NO20043569L
NO20043569L NO20043569A NO20043569A NO20043569L NO 20043569 L NO20043569 L NO 20043569L NO 20043569 A NO20043569 A NO 20043569A NO 20043569 A NO20043569 A NO 20043569A NO 20043569 L NO20043569 L NO 20043569L
Authority
NO
Norway
Prior art keywords
metabolites
sulfonyl
phenoxy
pyridine
tert
Prior art date
Application number
NO20043569A
Other languages
English (en)
Norwegian (no)
Other versions
NO20043569D0 (no
Inventor
Kimberly O'keefe Cameron
Bruce Allen Lefker
Kim Anne Johnson
Chandra Aggarwal Prakash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20043569D0 publication Critical patent/NO20043569D0/no
Publication of NO20043569L publication Critical patent/NO20043569L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20043569A 2002-01-31 2004-08-26 Metabolitter av(3-{[4-tert-butyl-benzyl)-(pyridin-3-sulfonyl)-amino]-metyl}-fenoksy)-eddiksyre NO20043569L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35374802P 2002-01-31 2002-01-31
PCT/IB2003/000121 WO2003064391A1 (en) 2002-01-31 2003-01-20 Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid

Publications (2)

Publication Number Publication Date
NO20043569D0 NO20043569D0 (no) 2004-08-26
NO20043569L true NO20043569L (no) 2004-08-26

Family

ID=27663249

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043569A NO20043569L (no) 2002-01-31 2004-08-26 Metabolitter av(3-{[4-tert-butyl-benzyl)-(pyridin-3-sulfonyl)-amino]-metyl}-fenoksy)-eddiksyre

Country Status (30)

Country Link
US (1) US6852863B2 (is)
EP (1) EP1470109A1 (is)
JP (1) JP2005521668A (is)
KR (1) KR20040077884A (is)
CN (1) CN1625549A (is)
AP (1) AP2004003094A0 (is)
AR (1) AR038332A1 (is)
BR (1) BR0307339A (is)
CA (1) CA2473984A1 (is)
EA (1) EA200400724A1 (is)
EC (1) ECSP045215A (is)
GB (1) GB2400100B (is)
HN (1) HN2003000051A (is)
HR (1) HRP20040683A2 (is)
HU (1) HUP0500012A2 (is)
IL (1) IL162167A0 (is)
IS (1) IS7281A (is)
MA (1) MA27169A1 (is)
MX (1) MXPA04004960A (is)
NO (1) NO20043569L (is)
OA (1) OA12760A (is)
PA (1) PA8564601A1 (is)
PE (1) PE20030978A1 (is)
PL (1) PL371982A1 (is)
PY (1) PY0300568A (is)
TN (1) TNSN04138A1 (is)
TW (1) TW200302080A (is)
UY (1) UY27632A1 (is)
WO (1) WO2003064391A1 (is)
ZA (1) ZA200404067B (is)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US7666330B2 (en) * 2005-04-20 2010-02-23 Lg Chem, Ltd. Additive for non-aqueous electrolyte and secondary battery using the same
NZ573964A (en) * 2006-07-28 2010-11-26 Pfizer Prod Inc isopropyl [3-({[4-(1H-pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)-amino}methyl)phenoxy]acetate, a prostaglandin E2 receptor agonist (EP2), useful in lower intraocular pressure thereby treating glaucoma
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
TR201904655T4 (tr) * 2008-03-12 2019-06-21 Ube Industries Piridilaminoasetik asit bileşiği.
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2337563B1 (en) * 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
KR101681347B1 (ko) 2009-03-30 2016-11-30 우베 고산 가부시키가이샤 녹내장의 치료 또는 예방을 위한 의약 조성물
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
TNSN04138A1 (fr) 2007-03-12
TW200302080A (en) 2003-08-01
MA27169A1 (fr) 2005-01-03
HUP0500012A2 (hu) 2005-04-28
JP2005521668A (ja) 2005-07-21
EA200400724A1 (ru) 2004-12-30
KR20040077884A (ko) 2004-09-07
WO2003064391A1 (en) 2003-08-07
GB2400100A (en) 2004-10-06
NO20043569D0 (no) 2004-08-26
UY27632A1 (es) 2003-08-29
GB0413967D0 (en) 2004-07-28
GB2400100B (en) 2006-04-12
ZA200404067B (en) 2005-08-29
AR038332A1 (es) 2005-01-12
PY0300568A (es) 2004-10-01
IS7281A (is) 2004-05-21
HN2003000051A (es) 2003-09-24
CN1625549A (zh) 2005-06-08
PL371982A1 (en) 2005-07-11
MXPA04004960A (es) 2005-04-08
AP2004003094A0 (en) 2004-09-30
CA2473984A1 (en) 2003-08-07
PA8564601A1 (es) 2003-09-05
IL162167A0 (en) 2005-11-20
US6852863B2 (en) 2005-02-08
PE20030978A1 (es) 2003-11-19
EP1470109A1 (en) 2004-10-27
ECSP045215A (es) 2004-09-28
HRP20040683A2 (en) 2004-10-31
OA12760A (en) 2006-07-04
US20030216445A1 (en) 2003-11-20
BR0307339A (pt) 2004-12-07

Similar Documents

Publication Publication Date Title
NO20043569D0 (no) Metabolitter av(3-{[4-tert-butyl-benzyl)-(pyridin-3-sulfonyl)-amino]-metyl}-fenoksy)-eddiksyre
CY2016042I1 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO20050118D0 (no) Substituerte fenylsulfonamidinhibitorer av beta-amyolid produksjon
DE60336251D1 (de) Identifikation von aufzeichnungsmedien
CY2015015I1 (el) Παραγωγη τιακουμυκινης
NO20032645L (no) Heterocykliske sulfonamidinhibitorer av <beta>- amyloidproduksjonen
NO20043726L (no) Heteroarylforbindelser anvendelige som inhibitorer av GSK-3
DK1660431T3 (da) Phenoxyeddikesyrederivater
PL378181A1 (pl) Pochodne kwasu hydroksamidowego jako inhibitory deacetylazy histonowej (HDAC)
EE200300343A (et) Pantoteenhappe võimendatud produktsiooni meetod
NO20050346D0 (no) Nitro-oksyderivater av syklooksygenase-2-inhibitorer
DE60216641D1 (de) Polymorph von 4-ä2-ä4-ä1-(2-ethoxyethyl)-1h-benzimidazol-2-ylü-1-piperidinylüethylü-alpha, alpha-dimethylbenzolessigsäure
AU2003299095A1 (en) Synthesis of thiophenecarboxylic acid esters for the production of ranelic acid salts
NO20050563L (no) N-aryl-piperidinsubstituerte bifenylkarboksamider som inhibitorer av apolipoprotein B-sekresjon
NO20054408D0 (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
ATE338027T1 (de) Herstellung von iminodiessigsäure-derivaten aus monoethanolamin-substraten
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
PL371629A1 (pl) Sposób wytwarzania kombrestatyn
AP1942A (en) New process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates.
NO20023921D0 (no) Derivater av thiazepinylhydroksamisk syre som inhibitorer av matriks metalloproteinase
CY2011018I1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
IS8232A (is) Lyfjafræðilega gagnleg sölt karboxýlsýruafleiða
DE60323748D1 (de) 1,3-diaza-dibenzoazulene als inhibitoren der produfür deren herstellung
NO20021965D0 (no) Hydroksamsyrederivat som inhibitor av dannelsen av opplöselig, human CD23
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application